174 related articles for article (PubMed ID: 15154652)
1. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
Dohmen W; Breier M; Mengs U
Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
[TBL] [Abstract][Full Text] [Related]
2. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Semiglazov VF; Stepula VV; Dudov A; Schnitker J; Mengs U
Anticancer Res; 2006; 26(2B):1519-29. PubMed ID: 16619567
[TBL] [Abstract][Full Text] [Related]
3. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
[TBL] [Abstract][Full Text] [Related]
4. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
Mengs U; Witthohn K; Schwarz T; Lentzen H
Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
[TBL] [Abstract][Full Text] [Related]
5. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Semiglasov VF; Stepula VV; Dudov A; Lehmacher W; Mengs U
Anticancer Res; 2004; 24(2C):1293-302. PubMed ID: 15154663
[TBL] [Abstract][Full Text] [Related]
6. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
[TBL] [Abstract][Full Text] [Related]
7. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.
Weber K; Mengs U; Schwarz T; Hajto T; Hostanska K; Allen TR; Weyhenmeyer R; Lentzen H
Arzneimittelforschung; 1998 May; 48(5):497-502. PubMed ID: 9638318
[TBL] [Abstract][Full Text] [Related]
8. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract.
Heiny BM; Albrecht V; Beuth J
Anticancer Res; 1998; 18(1B):583-6. PubMed ID: 9568181
[TBL] [Abstract][Full Text] [Related]
9. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.
Schumacher K; Schneider B; Reich G; Stiefel T; Stoll G; Bock PR; Hanisch J; Beuth J
Anticancer Res; 2003; 23(6D):5081-7. PubMed ID: 14981970
[TBL] [Abstract][Full Text] [Related]
10. [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients].
Beuth J; Stoffel B; Ko HL; Buss G; Tunggal L; Pulverer G
Arzneimittelforschung; 1995 Apr; 45(4):505-7. PubMed ID: 7779151
[TBL] [Abstract][Full Text] [Related]
11. Immunoprotective activity of the galactoside-specific mistletoe lectin in cortisone-treated BALB/c-mice.
Beuth J; Ko HL; Tunggal L; Buss G; Jeljaszewicz J; Steuer MK; Pulverer G
In Vivo; 1994; 8(6):989-92. PubMed ID: 7772751
[TBL] [Abstract][Full Text] [Related]
12. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
Gabius S; Gabius HJ
Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
[No Abstract] [Full Text] [Related]
13. [Immunoactive action of mistletoe lectin-1 in relation to dose].
Beuth J; Ko HL; Tunggal L; Buss G; Jeljaszewicz J; Steuer MK; Pulverer G
Arzneimittelforschung; 1994 Nov; 44(11):1255-8. PubMed ID: 7848341
[TBL] [Abstract][Full Text] [Related]
14. Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models.
Braun JM; Ko HL; Schierholz JM; Beuth J
Anticancer Res; 2002; 22(6C):4187-90. PubMed ID: 12553054
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
[TBL] [Abstract][Full Text] [Related]
16. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients.
Heiny BM; Beuth J
Anticancer Res; 1994; 14(3B):1339-42. PubMed ID: 8067703
[TBL] [Abstract][Full Text] [Related]
17. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.
Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R
Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650
[TBL] [Abstract][Full Text] [Related]
18. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract.
Stein GM; Berg PA
Eur J Med Res; 1998 Jun; 3(6):307-14. PubMed ID: 9620894
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588
[TBL] [Abstract][Full Text] [Related]
20. Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats.
Kunze E; Schulz H; Ahrens H; Gabius HJ
Exp Toxicol Pathol; 1997 Aug; 49(3-4):167-80. PubMed ID: 9314050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
